The Government of Canada has announced a $79 million contribution to Vancouver-based Aspect Biosystems through its Strategic Response Fund, part of a broader $280 million multi-year project to accelerate the development and biomanufacturing of the company's pipeline of bioengineered cellular medicines. The announcement was made at Aspect's Vancouver headquarters by the Honourable Mélanie Joly, Minister of Industry.
The scale is notable. It builds on a $200 million co-investment from the Government of Canada and the Province of British Columbia in 2024, and follows a US$115 million Series B the company closed in 2025. The Province of B.C. has also contributed an additional $23.8 million to support the company's current expansion.
"This investment from the Government of Canada is a powerful vote of confidence and adds to the significant momentum at Aspect as we advance our bioengineered cellular medicines towards patient impact," said Tamer Mohamed, CEO of Aspect Biosystems. "We are taking a major step toward building a generational company anchored in Canada and delivering life-changing therapies to patients around the world."
Aspect is developing a new category of regenerative medicine, one designed not to manage disease but to restore or supplement biological function in the body. The company is targeting functional cures for serious metabolic and endocrine conditions, including diabetes. To do that, Aspect has built what it calls a full-stack platform combining proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials. The hypoimmune engineering piece is central to the approach: it's designed to allow the body to accept bioengineered cellular medicines without triggering immune rejection, one of the core challenges in cell therapy.
The new federal investment will strengthen Aspect's clinical development capabilities and its vertically integrated biomanufacturing platform, meaning the company controls more of the development and production process in-house, in Canada.
Earlier this year, Aspect entered a new phase of its partnership with Novo Nordisk, the Danish pharmaceutical giant. Under the expanded collaboration, originally announced in April 2023, Aspect is integrating additional stem cell and hypoimmune cell engineering technologies from Novo Nordisk into its platform while taking on expanded research, development, and manufacturing responsibilities.
The federal government framed the announcement in terms of both health care and economic strategy. The project is expected to maintain 117 existing jobs and create 283 new positions in the Vancouver region, along with 268 student co-op placements. "By investing in the development and commercialization of cutting-edge cellular medicines, our government is helping to create high-quality jobs, drive economic growth, and position Canada as a leader in biotechnology," said the Honourable Mélanie Joly.
The Aspect investment was part of a broader $127 million announcement that also included a $48 million contribution to Providence Health Care to support an innovation hub within the new Clinical Support and Research Centre on the Jim Pattison Medical Campus.